Maged Shenouda, Chief Financial Officer of Relmada Therapeutics, Inc. (NASDAQ:RLMD), filed a Form 4 on September 11, 2026, disclosing open market purchases of 200,000 shares of common stock across two trading days, September 9 and September 10, 2026.

Key Highlights

  • First purchase: 120,200 shares acquired on September 9, 2026, at a weighted average price of $4.20 per share, with individual transaction prices ranging from $4.16 to $4.20 per share, inclusive.
  • Second purchase: 79,800 shares acquired on September 10, 2026, at $4.25 per share.
  • Total shares purchased: 200,000 shares of common stock over the two-day period, both transactions coded as open market purchases (Code P).
  • Resulting ownership: Following both transactions, Shenouda directly beneficially owns 1,000,000 shares of common stock.
  • Reporting person role: Shenouda is identified in the filing as Chief Financial Officer of Relmada Therapeutics, Inc.

Relmada Therapeutics CFO Discloses Two-Day Open Market Purchase of Common Stock

According to the Form 4 filed with the U.S. Securities and Exchange Commission on September 11, 2026, Maged Shenouda, the Chief Financial Officer of Relmada Therapeutics, Inc., purchased a combined 200,000 shares of the company's common stock in open market transactions on September 9 and September 10, 2026. Both transactions are reported as direct ownership and carry transaction code "P," indicating open market purchases.

The filing discloses that the September 9 transaction involved 120,200 shares at a weighted average price of $4.20 per share. As noted in the filing's explanatory footnotes, this figure represents an aggregate of multiple open market transactions. The filing states that "purchase prices range from $4.16 to $4.20 per share, inclusive," and Shenouda "undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range." Prior to these reported transactions, Shenouda's beneficial ownership stood at 800,000 shares, based on the post-transaction figure of 920,200 shares following the first purchase.

The September 10 purchase consisted of 79,800 shares at a price of $4.25 per share. After this second transaction, Shenouda's directly held beneficial ownership totaled 1,000,000 shares of Relmada Therapeutics common stock, according to the filing. No derivative securities transactions were reported in Table II of the form.

What Was Disclosed

The filing reports two open market common stock purchases by Relmada Therapeutics' CFO totaling 200,000 shares on September 9 and 10, 2026, at prices of $4.20 (weighted average) and $4.25 per share, bringing his direct beneficial ownership to 1,000,000 shares.